AU2004218876B2 - Novel compositions containing fentanyl - Google Patents
Novel compositions containing fentanyl Download PDFInfo
- Publication number
- AU2004218876B2 AU2004218876B2 AU2004218876A AU2004218876A AU2004218876B2 AU 2004218876 B2 AU2004218876 B2 AU 2004218876B2 AU 2004218876 A AU2004218876 A AU 2004218876A AU 2004218876 A AU2004218876 A AU 2004218876A AU 2004218876 B2 AU2004218876 B2 AU 2004218876B2
- Authority
- AU
- Australia
- Prior art keywords
- formulation
- formulation according
- fentanyl
- container
- polar organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
WO 2004/080382 PCT/GB2004/001037 Novel Compositions This invention relates to formulations of fentanyl, especially pump spray formulations suitable for sublingual delivery.
Fentanyl is a narcotic alkaloid, which has been used for many years as an anaesthetic and an analgesic, especially in the treatment of moderate to severe pain. Whilst undoubtedly effective for pain relief, and especially in the treatment of pain which is refractive to other treatments, there are a number of issues of clinical management 1o associated with the use of fentanyl in therapy.
Foremost amongst these issues is the potential for serious side effects with fentanyl.
It has a much higher potency than commonly known narcotics and therefore it is necessary to ensure that it is being used within the established therapeutically effective range and to monitor patients for evidence of self medication at greater than the recommended amount. Overdosage with fentanyl can lead to a number of undesirable and indeed life-threatening side effects, predominantly hypoventilation and respiratory depression.
Due to the nature of the conditions being treated, it is much desired that the onset of analgesia occurs as soon after dosage as is compatible with safety parameters.
Furthermore delay in onset of action may prompt the patient to take another dose with consequent risk, as already explained above, of overdosage.
A number of routes of administration of a medicament can be associated with rapid onset of action. For example, International Patent Application W090/07333 (Riker Labs) described aerosol formulations of fentanyl, which are adapted for inhalation.
However Riker's formulations suffer disadvantages such as their use of hydrofluorocarbon propellants and delivery effected by metered dose inhalers. In the case of the former the disadvantages include high velocity which results in 'bounce back' on administration to the front of the mouth, cold sensations on administration, the risk of inhalation and for the latter, careful co-ordination of -U breath and actuation by the patient When metered dose inhalers are used, a significant t proportion of the delivered dose tends to impact the back of the throat from where it is swallowed rather than finding its way into the bronchial passages. Accordingly, the pharmacology of the medication may be unpredictable due to poor bioavailability following oral administration or may be characterised by a bi-phasic profile (fast initial onset as a result of the \O inhaled dose and a slower, late effect due to oral absorption of fentanyl). Furthermore, 1 manufacture of the bulk formulation involves the preparation of large quantities of pressurised 00 volatile propellant containing a potent narcotic analgesic. Acordingly the precautions required C1 to ensure safe manufacture are onerous and expensive.
010 Ci W095/31182 (Aradigm Corp) describes solution formulations of fentanyl in aerosol propellants intended for administration to patients by the pulmonary mute.
WO01/97780 (Pharmasol Ltd) describes solution formulations of fentanyl free base in propellants, typically HFA134a, for sublingual aerosol administration.
WO00/47203 (MQS Inc) describes formulations of fentanyl citrate for intra-oral administration employing oral absorption enhancers.
These prior art formulations of fentanyl employ propellants and also suffer from the aforementioned disadvantages.
Certain aqueous formulations of fentanyl for intranasal administration employing water and phosphate buffer have been described, (Paech, MJ., Lim, Banks, S.L, Rucklidge, M. W.
M. Doherty, DA (2003) Anaesthesia 58 740-744 and Inm et al (2003) J Phann Practice Research 33, 59-63) but such formulations can suffer problems of nasal initation associated with medium to long term usage via this route which is undesirable. Weinberg et al (1988) Clin Pharmacol Therap 44 335-342 discloses formulations of fentanyl employing water and phosphate buffer for sublingual administration however these formulations were not advocated foruseas a spray.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base orwere common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
t It is well known that the application of carefully chosen.medicaments to the sublingual mucosa t offers a route of administration which is capable of resulting in very rapid transmission of medicament to the bloodstream with consequent fast onset of effect A number of ways of administering compositions sublingually are known. For example, tablets or liquids may be held under the tongue prior to swallowing.. Another method is spray delivery. Of these various IN types of sublingual administration, spray delivery is preferred as it does not involve holding the composition under the tongue for an extended period of time as, for example, with a lozenge 00 and it reduces the amount of material which is swallowed (and may enter the blood stream in a C delayed manner via the gastrointestinal tract). Pharmaceutical compositions, for example a 0 10 fentanyl lozenge cause increased salivation, which facilitates the unwanted swallowing of drug CN substance. Spray delivery, having low volume and ability to target the sublingual mucosa, largely mitigates this. No propellant free spray formulations of fentanyl which are adapted for sublingual administration have yet been described.
It is an aim of the present invention to provide a formulation, which avoids or mitigates some or all of the above-mentioned disadvantages.
Thus according to a first aspect of the invention a pharmaceutical composition is provided, the composition being a partially pressurised liquid spray formulation, which comprises: fentanyl or a pharmaceutically acceptable salt thereof; water as carrier and a polar organic solvent in sufficient amount to enhance the solubility of the fentanyl or pharmaceutically acceptable salt thereof in the water.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising', will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The formulations of the invention are preferably administered sublingually as a spray. The formulations are well tolerated when administered to the sensitive sublingual mucosa and the sublingual spray administration will result in rapid onset of the therapeutic effect of the fentanyl.
WO 2004/080382 PCT/GB2004/001037 -4- The formulations of the present invention are also preferably free of any propellant.
Amongst the advantages of these formulations is the fact that by being water based they avoid the issues associated with using pressurised hydrofluorocarbon propellants as mentioned above. The formulations are partially pressurised and are free of propellants such as volatile chlorofluorocarbons propellant 12), volatile hydrofluoroalkanes 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoro-npropane) and volatile alkanes propane, butane) and other substances which have significant vapour pressure at ambient temperature and pressure.
In one embodiment of the present invention, the formulation is a solution, rather than a suspension. Whilst it is possible to spray a suspension, the fact that most suspensions settle means that the amount of active agent included in the dispensed dose will be variable and this can be highly undesirable. Although the effect of the settling of the suspension can be reduced to an extent by shaling the composition prior to spraying, some suspensions can settle very rapidly, so that there is still potential for variation of active agent content between doses.
Furthermore the formulations of the present invention are characterised by good long-term physical and chemical stability.
Fentanyl may be employed in the form of a physiologically acceptable salt, which is soluble in water together with a polar organic solvent. Examples of suitable salts include hydrochloride, chloride, sulphate, tartrate and citrate. Preferably fentanyl is employed as the free base.
Preferably the fentanyl or physiologically acceptable salt thereof will be employed in the formulation at a concentration of 0.1mg/ml to 10mg/ml, preferably to 4.4mg/ml (where weight is expressed as weight of fentanyl free base).
WO 2004/080382 PCT/GB2004/001037 Examples of polar organic solvents that may be used to enhance the solubility of fentanyl, or the physiologically acceptable salt thereof in the water, include: lower alcohols C 2 4 alcohols) such as ethanol; lower polyols C 2 -4 polyols) such as glycerol and propylene glycol; and polyethylene glycols such as PEG200 and PEG400.
Mixtures of the above substances may be used. The preferred polar organic solvent is ethanol.
In another embodiment of the present invention, the formulation does not include ethanol. Indeed, the formulation may be substantially free of any alcohol, or completely free of alcohol.
Where the composition is free of alcohol, the carrier used is preferably a polyol.
The preferred polyols include propylene glycol and glycerol.
Generally speaking it will be desired to employ the least amount of polar organic solvent necessary (or a modest excess over that necessary) to adequately solubilise the fentanyl, or physiologically acceptable salt thereof, and such that the fentanyl remains in solution under the conditions of likely usage or exposure.
The concentration of polar organic solvent is in the range preferably of between 6 and 50%, more preferably 20-45% especially 35-42%.
Preferably the water meets the USP (US Pharmacopoeia), EP (European Pharmacopoeia) "Purified Water" standards.
It has also been found that the properties of the claimed formulations may be improved by including therein a number of additional formulations components.
Thus, in one embodiment of the invention, the water in the formulation is present in the form of an aqueous buffer. The buffer is preferably adapted to stabilise the WO 2004/080382 PCT/GB2004/001037 -6pH of the formulation at pH 7.4 to 8.5, preferably at pH 8.0 to 8.5, more preferably at 8.1 to 8.3, or around 8.2. At higher pH values we have found evidence that the bioavailability of the formulation is improved relative to lower pH values (e.g.
nearer pH Example buffer systems include sodium acetate/acetic acid, ammonium acetate/disodium edetate, boric acid/sodium hydroxide, orthophosphoric acid/sodium hydroxide, sodium hydrogen carbonate/sodium carbonate, disodium hydrogen orthophosphate/citric acid (taken from the British Pharmacopoeia). The preference is use of a citrate buffer, e.g. a buffer comprising citric acid, sodium citrate and sodium hydroxide.
The concentration of the aqueous component (water or more preferably aqueous buffer) of the formulation of the present invention is preferably 50-94%, more preferably 55-80%, and especially 58-65%.
It may be desirable to include one or more of the following components in the formulation.
1) Sweeteners, flavouring or taste-masking agents (to improve patient acceptability), for example vanilla, pineapple extract, menthol, saccharin and sodium saccharin.
2) Moisturising agents (to improve patient comfort and overcome the drying tendency of ethanol and other polar organic solvents), for example pineapple extract, lanolin, polypropylene glycol, and polyethylene glycol.
3) Penetration enhancers (to improve therapeutic effect), for example menthol.
4) Mucoadherents (in order to increase residency time on the mucosa), for example carboxyvinyl polymers, chitosans, polyacrylic acid, gelatin and polyvinyl pyrrolidone.
5) Preservatives (to improve long term resistance to microbial contamination), for example ethanol, sodium metabisulphite, benzalkonium chloride and Nipas.
6) Antioxidants, for example Alkyl Gallates, Butylated Hydroxyanisole, Butylated Hydroxytoluene, Nordihydroguaiaretic acid, Tocopherols, Ascorbic acid and Sodium metabisulphite.
7) Anionic surfactants, for example Magnesium Stearate, Sodium Cetostearyl sulphate, Sodium Lauryl sulphate, Sulphated caster oil, Sodium oleate, Sodium stearyl Fumarate and Sodium Tetradecyl Sulphate.
WO 2004/080382 PCT/GB2004/001037 -7- 8) Nonionic surfactants, for example Glyceryl Monostearate, Macrogol Cetostearyl Ethers, Poloxamers, Polyoxyl Stearates, Polysorbates, Sorbitan Esters, Sucrose Esters, Tyloxapol, Propylene Glycol Monostearate, Quillaia, Polyoxyl Caster Oils, Nonoxinols, Lecithins and derivatives, Oleic acid and derivatives, Oleyl alcohol and derivatives.
9) Foaming agents, for example Alginic Acid and salts, Propylene Glycol Alginate, Sodium Lauryl sulphate, Sodium Cetostearyl sulphate, carbomers, Hydroxyethylcellulose Some of the components proposed above may already be included in the composition of the present invention for other purposes. Suitable moisturising agents include, for example, the polar organic solvents such as glycols, especially propylene glycol, and the liquid polyethylene glycols, glycerol, methylcellulose, hypromellose, hydroxypropylcellulose, and many other substituted celluloses.
A versatile component, which improves the acceptability and other properties of the formulation, is menthol. Menthol, as well as flavouring the formulation, has moisturising effect. It may also have effect as a penetration enhancer. Preferably menthol is employed in a concentration range of 0.25% to One particular advantage of menthol is that it is compatible with fentanyl in a spray formulation unlike peppermint oil (of which menthol is one component), which causes fentanyl to degrade.
In an embodiment of the invention, the formulation contains a sweetener. The preferred sweetener is saccharin or a physiologically acceptable salt thereof such as saccharin sodium. Preferably the concentration of sodium saccharin or physiologically acceptable salt thereof is around e.g. around 0.28%.
Preferably the formulation contains saccharin. Surprisingly, we have found that the longer-term stability of formulations containing saccharin is better than the stability of those containing saccharin sodium.
WO 2004/080382 PCT/GB2004/001037 -8- It has been discovered that it is not generally necessary to include a preservative in the formulation when ethanol is present due to its preservative qualities.
Formulations of the invention are useful in analgesia and in the treatment of pain.
In a further aspect of the invention, formulations according to the first aspect of the invention are provided for use in the treatment of moderate to severe pain. In a yet further aspect of the invention, the use of the formulations according to the invention in the manufacture of a medicament for analgesia or for the treatment of pain is provided. In one embodiment, a therapeutically effective amount of a formulation for the treatment of pain according to the invention is used.
Formulations according to the invention are preferably packaged as a bulk solution containing multiple doses in a pump spray system comprising a sealed container fitted with a metering pump. Thus as an aspect of the invention we provide a sealed container containing a plurality of doses of a formulation according to the invention. The container will preferably contain between 20 to 200 doses. Example containers are those made out of plastics, glass and metal aluminium) however glass containers are preferred. Glass containers have the advantage that the contents of the container can be seen it is possible to determine visually when the contents are about to run out). Furthermore glass containers are less susceptible to tampering, which is an important consideration for narcotic substances.
In another embodiment, single or multiple use devices comprising a single or multiple dose of the formulation of the invention is envisaged.
Preferably the glass container will be coated on the exterior with a suitable moulded film of plastic to protect against shattering. For example the film may be of polypropylene. The material may be coloured and contain a UV absorber.
Optionally, the interior of the containers can be coated to enhance stability of the WO 2004/080382 PCT/GB2004/001037 -9product. Coatings include polymers and lacquers but also silicone dioxide can be used to line the inside of the container with an unreactive coating.
Another aspect of the invention is a metered dose dispensing system comprising a sealed container containing a formulation of the invention fitted with a metering pump, an actuator and a channelling device. The metered dose dispensing system is preferably adapted for sublingual administration.
Suitable metering pumps include those adapted for dispensation with the container in the upright or inverted orientation. Preferably the metering chamber is adapted for dispensation with the container in the upright orientation since this facilitates administration under the tongue. Accordingly the metering chamber will be in communication with the bulk formulation by means of a dip-tube.
Example metering pumps are those manufactured by Valois and illustrated in International Patent Application No. W001/66089.
The metering pump is preferably a non-venting type with a dip tube. Such nonventing metering pumps may have, for example, a 100(l metering chamber capacity.
The materials of construction include polypropylene and polyethylene. Suitable sealing materials, e.g. thermoplastic crimp gaskets suitable for the purpose will be employed. In addition, a suitable aluminium ferrule purposely designed for crimping on to glass containers may suitably be employed. Suitable grade stainless steel springs will preferably be adopted.
Preferably the actuator will be designed to deliver a sublingually effective dose. The package may be further enhanced by the fitting of a lock-out system to promote compliance by patients.
Typically a patient is treated by administration sublingually of 1 to 4 actuations, e.g.
1 or 2 actuations from the spray pump. Another advantage of sublingual spray delivery is the ability to easily titrate patients by 1 or 2 doses as required by a single WO 2004/080382 PCT/GB2004/001037 actuation. This is not the case with other forms of drug delivery (patches, lozenges, tablets, suppositories).
One of the possible methods for preparing certain formulations and filled containers according to the invention is shown in the figures, for illustrative purposes.
Figure 1 is a flow-chart showing the first stage of the method of preparing a formulation comprising 400g fentanyl.
Figure 2 is a flow-chart showing the second stage of the method.
Other formulations of the invention may be prepared by analogous methods, or methods known to a skilled person.
Weight percentage values given herein are expressed as w/w.
The formulations and products of the invention have better physical and chemical stability, are more environmentally friendly, are more conveniently or safely administered to patients, are more conveniently or safely manufactured, are more economical to manufacture, or have other advantages relative to prior art formulations and products.
The invention will now be illustrated by reference to the following examples: General Citrate buffer when employed contained: Citric acid 2.0 Sodium citrate 1.0 Sodium Hydroxide water: to 100% pH 8.2 (adjusted with NaOH).
WO 2004/080382 WO 2041080382PCTiGB2004/001037 11 Example 1 Formulation (pet container): Fentanyl base 0.0280g Saccharin 0.0177g Absolute ethanol 2 .8 3 3 6 g Menthol 0.05 3 1g Citrate buffet 4.1 5 1 6 g The target dose is 4 OO tg per actuation.
Example 2 Formulation (per container): Fentanyl base 0.0 2 Saccharin sodium 0.0l 9 8g (equivalent to 0.0177g saccharin) Absolute ethanol 2 8 3 3 6 g Menthol 0.05 3 1g Citrate buffer 4 .1 5 1 6 g The target dose is 4OO Lg per actuation of lOO0il.
Examp le 3 Formulation (per container): Fentanyl base 0.0 2 Saccharin 0.017 7 g Absolute ethanol 2.
8 3 3 6 g Citrate buffer 4.07 The target dose is 4OO rg per actuation of 1OO Ll.
Example 4 Formulation (per container): Fenranyl base 0.0 2 Saccharin sodium 0.0Oi 9 8 g (equivalent to 0.01'77g saccharin) Absolute ethaniol 2 8 3 3 6 g WO 2004/080382 PCT/GB2004/001037 -12- Water 4 2 0 2 6 g The target dose is 4 00tig per actuation of 100 l.
Example Formulation (per container): Fentanyl base 0.
0 1 4 0 g Saccharin sodium 0.
0 1 9 8 g (equivalent to 0.
0 1 7 7 g saccharin) Absolute ethanol 2.8 3 3 6 g Menthol 0.0531g Citrate buffer 4.1656g The target dose is 200[pg per actuation of 1001ll.
Packaging of formulations The example formulations may be packaged into a suitable coated glass container and fitted with a suitable non-venting metered dose pump. An actuator suitable for sublingual delivery may be fitted.
Test data The formulation of Example 1 was subjected to the following tests.
Units were placed on stability storage at 5 0 C, 25 0 C/60% RH, 30 0 C/65% RH and 0 C/75% RH. For each test 3 replicates were assessed.
a) Appearance (including clarity).
Observation be made and the results recorded.
b) Mean Weight of Expelled Dose (Shot weight) Each unit will be weighed before and after test sprays. From these measurements, mean shot weight will be calculated by difference calculation c) pH pH is measured on a single unit at each time point at each condition. The unit is opened under controlled conditions and the pH measured by use of a pH meter.
WO 2004/080382 PCT/GB2004/001037 13d) Degradation Products A sample of the formulation from each unit was taken and examined for degradation products by HPLC assay. The result was recorded as 'none', (no identification) or percentage of identified degradant.
The results were as follows: Test Condition A Condition B Condition C Condition D (Specification) Appearance Pass Pass Pass Pass (clear, no particles, colourless) Shotweight Pass Pass Pass Pass 110mg) pH (7.7 8.7) 8.2 8.2 8.2 8.2 Degradation ND ND ND <0.1% product A Degradation ND ND ND 0.1-0.15% product B The formulation of Example 2 was subjected to the same tests, with the following results: Test Condition A Condition B Condition C Condition D Appearance Pass Pass Pass Pass (clear, no particles, colourless) Shotweight Pass Pass Pass Pass 110mg) pH (7.7 8.7) 8.3 8.3 8.3 8.3 Degradation ND ND ND <0.1% product A Degradation ND ND ND <0.1% product B Condition A: 2-8'C, ambient humidity Condition B: 25 0 C, 60% relative humidity WO 2004/080382 PCT/GB2004/001037 -14- Condition C: 30'C, 60% relative humidity Condition D: 40 0 C, 75% relative humidity Appearance: all samples were clear and colourless with no particles.
Shotweight: all samples were within target.
pH: stable Moisture content: acceptable.
Degradation products A and B: none detected.
From the test results, it was concluded that the tested formulations of the invention demonstrate excellent physical and chemical stability.
Claims (12)
1. A pharmaceutical liquid formulation comprising: fentanyl free base; water as carrier; C") a polar organic solvent in sufficient amount to enhance the solubility of the fentanyl O in the water; and r a buffer, wherein the pH of the formulation is 7.4 to 00 00 CK1 2. A formulation according to claim I, wherein the buffer is a citrate buffer. S3. A formulation according to claim 2, wherein the citrate buffer comprises citric acid, sodium citrate and sodium hydroxide.
4. A formulation according to any one of the preceding claims, wherein the fentanyl free base is present at a concentration of 0.1-10 mg/ml. A formulation according to any one of the preceding claims, wherein the polar organic solvent is selected from ethanol, propylene glycol, glycerol, polyethylene glycol and mixtures thereof.
6. A formulation according to claim 5, wherein the polar organic solvent is ethanol.
7. A formulation according to any one of the preceding claims, wherein the polar organic solvent is present in an amount of 6-50% w/w.
8. A formulation according to any one of the preceding claims, wherein the pH is around 8.2.
9. A formulation according to any one of the preceding claims, which contains a sweetener. A formulation according to claim 9, wherein the sweetener is saccharin, or saccharin sodium.
11. A formulation according to any one of the preceding claims, which contains menthol. 494969 l.doc
12. A formulation according to any one of the preceding claims, when used for treating pain or as a method of analgesia. S13. Use of the components of a formulation according to any one of claims 1 to 11 in the manufacture of the formulation of a medicament for analgesia or for the treatment of pain. INO r14. Use according to claim 13, wherein the medicament is to be administered sublingually 00 0 as a spray.
15. A sealed container containing a plurality of doses of a formulation according to any one C, of claims 1 to 11.
16. A container according to claim 15, which is made out of glass.
17. A container according to claim 15 or claim 16, wherein the formulation is partially pressurised.
19. A metered dose dispensing system comprising a container according to any one of claims 15 to 17 and fitted with a metering pump, an actuator and a channelling device. 19. A metered dose dispensing system according to claim 18, containing a metering chamber which is adapted for dispensation of the formulation with the container in the upright orientation and wherein the metering chamber is in communication with the formulation by means of a dip-tube. A pharmaceutical liquid formulation substantially as hereinbefore described with reference to the Examples, excluding any comparative examples. Dated this twenty-ninth day of May 2007 Arakis Ltd Patent Attorneys for the Applicant: F B RICE CO 494969 l.doc
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0305579.5A GB0305579D0 (en) | 2003-03-11 | 2003-03-11 | Pharmaceutical compositions |
GB0305579.5 | 2003-03-11 | ||
GB0328023.7 | 2003-12-03 | ||
GB0328023A GB2399286A (en) | 2003-03-11 | 2003-12-03 | Sub-lingual fentanyl formulation |
PCT/GB2004/001037 WO2004080382A2 (en) | 2003-03-11 | 2004-03-11 | Novel compositions containing fentanyl |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004218876A1 AU2004218876A1 (en) | 2004-09-23 |
AU2004218876B2 true AU2004218876B2 (en) | 2007-08-02 |
Family
ID=32992592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004218876A Ceased AU2004218876B2 (en) | 2003-03-11 | 2004-03-11 | Novel compositions containing fentanyl |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1608372A2 (en) |
JP (1) | JP2006519770A (en) |
KR (1) | KR20050115276A (en) |
AU (1) | AU2004218876B2 (en) |
BR (1) | BRPI0408209A (en) |
CA (1) | CA2516338A1 (en) |
MX (1) | MXPA05009602A (en) |
NO (1) | NO20054172L (en) |
NZ (1) | NZ541781A (en) |
WO (1) | WO2004080382A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5577021B2 (en) * | 2005-02-17 | 2014-08-20 | アボット・ラボラトリーズ | Transmucosal administration of pharmaceutical compositions for treating and preventing disorders in animals |
GB0514043D0 (en) * | 2005-07-08 | 2005-08-17 | Arakis Ltd | Fentanyl formulation |
CN101378735B (en) | 2006-01-25 | 2013-04-03 | 英西斯治疗学股份有限公司 | Sublingual fentanyl spray |
EP2180844B1 (en) | 2007-08-02 | 2018-02-21 | Insys Development Company, Inc. | Sublingual fentanyl spray |
GB2476494A (en) * | 2009-12-24 | 2011-06-29 | Norwich Pharma Technologies Ltd | Formulation for the sublingual delivery of sufentanil |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958379A (en) * | 1994-09-30 | 1999-09-28 | Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh | Pharmaceutical composition |
WO2000047203A1 (en) * | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
US20030035831A1 (en) * | 1998-12-21 | 2003-02-20 | Pankaj Modi | Pharmaceutical compositions for buccal delivery of pain relief medications |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1019019A1 (en) * | 1997-10-01 | 2000-07-19 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
SE9803239D0 (en) * | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
WO2002011778A1 (en) * | 2000-05-10 | 2002-02-14 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
DE10064219B9 (en) * | 2000-12-22 | 2009-02-12 | Nasalis Pain Relief International Gmbh | Novel pharmaceutical composition containing fentanyl and / or its derivatives |
-
2004
- 2004-03-11 JP JP2006500257A patent/JP2006519770A/en active Pending
- 2004-03-11 EP EP04719527A patent/EP1608372A2/en not_active Withdrawn
- 2004-03-11 WO PCT/GB2004/001037 patent/WO2004080382A2/en active IP Right Grant
- 2004-03-11 KR KR1020057016853A patent/KR20050115276A/en not_active Application Discontinuation
- 2004-03-11 MX MXPA05009602A patent/MXPA05009602A/en not_active Application Discontinuation
- 2004-03-11 BR BRPI0408209-5A patent/BRPI0408209A/en not_active IP Right Cessation
- 2004-03-11 AU AU2004218876A patent/AU2004218876B2/en not_active Ceased
- 2004-03-11 CA CA002516338A patent/CA2516338A1/en not_active Abandoned
- 2004-03-11 NZ NZ541781A patent/NZ541781A/en unknown
-
2005
- 2005-09-07 NO NO20054172A patent/NO20054172L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958379A (en) * | 1994-09-30 | 1999-09-28 | Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh | Pharmaceutical composition |
US20030035831A1 (en) * | 1998-12-21 | 2003-02-20 | Pankaj Modi | Pharmaceutical compositions for buccal delivery of pain relief medications |
WO2000047203A1 (en) * | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
Also Published As
Publication number | Publication date |
---|---|
KR20050115276A (en) | 2005-12-07 |
BRPI0408209A (en) | 2006-02-14 |
JP2006519770A (en) | 2006-08-31 |
NO20054172D0 (en) | 2005-09-07 |
WO2004080382A2 (en) | 2004-09-23 |
CA2516338A1 (en) | 2004-09-23 |
NZ541781A (en) | 2008-04-30 |
WO2004080382A3 (en) | 2005-03-24 |
NO20054172L (en) | 2005-10-06 |
EP1608372A2 (en) | 2005-12-28 |
AU2004218876A1 (en) | 2004-09-23 |
MXPA05009602A (en) | 2005-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060062812A1 (en) | Novel compositions | |
KR101757951B1 (en) | Combination therapy for copd | |
US20090270438A1 (en) | Novel compositions and formulations | |
AU2012204557B2 (en) | Bepotastine compositions | |
EP1904032B1 (en) | Fentanyl formulation containing an essential oil | |
KR101747474B1 (en) | Aerosol formulation for copd | |
WO2008047163A1 (en) | Buprenorphine-containing non-pressurised spray composition for transmucosal administration | |
CA2673049C (en) | Stable anti-nausea oral spray formulations and methods | |
KR20180030953A (en) | Compositions comprising azelastine and methods of use thereof | |
EA005179B1 (en) | Stable pharmaceutical solution formulations for pressurised metered dose inhalers | |
CZ281931B6 (en) | Sulfate of 3-£2-(dimethylamino)ethyl|-n-methyl-1h-indole-5-methane sulfonamide, and pharmaceutical preparations containing thereof | |
WO2009127878A1 (en) | A liquid spray solution comprising buprenorphine, ethanol and an antioxidant | |
US8802058B2 (en) | Pharmaceutical compositions and methods for administering the same | |
AU2004218876B2 (en) | Novel compositions containing fentanyl | |
ZA200506248B (en) | Novel compositions containing fentanyl | |
US20090180969A1 (en) | Pharmaceutical formulation comprising an anticholinergic drug | |
CA3150070A1 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |